{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:22:12Z","timestamp":1778581332425,"version":"3.51.4"},"reference-count":36,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,3,1]]},"abstract":"<jats:p>Advances in chemotherapy have led to a favorable long-term prognosis in approximately 50% of patients with aggressive non-Hodgkin lymphoma (NHL). However, the remaining patients do not enjoy such prolonged survival after standard treatment. New prognostic factors are needed to define this poor-prognosis group and to plan an appropriate treatment strategy. It has been reported that serum nm23-H1 protein may be a new prognostic factor for aggressive NHL. In the present study involving multiple institutions and a large number of patients, the level of nm23-H1 protein was compared among different types of lymphoma; it was lowest for indolent lymphoma, followed by aggressive lymphoma and then highly aggressive lymphoma. In addition, patients with aggressive NHL and higher nm23-H1 levels had worse overall and progression-free survival rates than those with lower nm23-H1 levels. The nm23-H1 level was also compared between patients with diffuse large B-cell lymphoma and patients with peripheral T-cell lymphoma. The results suggest that the level of nm23-H1 could serve as a prognostic factor in both groups. Moreover, the prognosis of lymphoma patients could be ascertained even more precisely by combining soluble interleukin-2 receptor or soluble CD44 and nm23-H1 levels. A multivariate analysis confirmed that the nm23-H1 level is an independent and important prognostic factor in aggressive NHL. Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma.<\/jats:p>","DOI":"10.1182\/blood.v97.5.1202","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"1202-1210","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"97","author":[{"given":"Nozomi","family":"Niitsu","sequence":"first","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Okabe-Kado","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Okamoto","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takagi","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadao","family":"Aoki","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Hirano","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Honma","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021220265330000_B1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-102-5-596","article-title":"MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.","volume":"102","author":"Klimo","year":"1985","journal-title":"Ann Intern Med."},{"key":"2020021220265330000_B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1991.9.1.25","article-title":"Superiority of Pro MACE-Cyta BOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.","volume":"9","author":"Longo","year":"1991","journal-title":"J Clin Oncol."},{"key":"2020021220265330000_B3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.leu.2401134","article-title":"Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkin's lymphoma.","volume":"12","author":"Niitsu","year":"1998","journal-title":"Leukemia."},{"key":"2020021220265330000_B4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med."},{"key":"2020021220265330000_B5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med."},{"key":"2020021220265330000_B6","first-page":"17","article-title":"Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.","volume":"25","author":"Miller","year":"1998","journal-title":"Semin Hematol."},{"key":"2020021220265330000_B7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.","volume":"336","author":"Gianni","year":"1997","journal-title":"N Engl J Med."},{"key":"2020021220265330000_B8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V70.3.624.624","article-title":"High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma.","volume":"70","author":"Pui","year":"1987","journal-title":"Blood."},{"key":"2020021220265330000_B9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-127-3-199708010-00002","article-title":"Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.","volume":"127","author":"Preti","year":"1997","journal-title":"Ann Intern Med."},{"key":"2020021220265330000_B10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10428199709051774","article-title":"Interleukin-10 in non-Hodgkin's lymphoma.","volume":"26","author":"Cortes","year":"1997","journal-title":"Leuk Lymphoma."},{"key":"2020021220265330000_B11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2141.1996.00377.x","article-title":"Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers.","volume":"92","author":"Christiansen","year":"1996","journal-title":"Br J Haematol."},{"key":"2020021220265330000_B12","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood.V90.10.4039","article-title":"Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.","volume":"90","author":"Ristamaki","year":"1997","journal-title":"Blood."},{"key":"2020021220265330000_B13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199708213370804","article-title":"Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.","volume":"337","author":"Ichikawa","year":"1997","journal-title":"N Engl J Med."},{"key":"2020021220265330000_B14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V87.1.265.265","article-title":"Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).","volume":"87","author":"Hermine","year":"1996","journal-title":"Blood."},{"key":"2020021220265330000_B15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.","volume":"331","author":"Offit","year":"1944","journal-title":"N Engl J Med."},{"key":"2020021220265330000_B16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jnci\/80.3.200","article-title":"Evidence for a novel gene associated with low tumor metastatic potential.","volume":"80","author":"Steeg","year":"1988","journal-title":"J Natl Cancer Inst."},{"key":"2020021220265330000_B17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/bies.950170111","article-title":"Nm23\/nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions.","volume":"17","author":"de la Rosa","year":"1995","journal-title":"Bioessays."},{"key":"2020021220265330000_B18","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/bjc.1996.616","article-title":"Variability of nm23\u2013H1\/NDPK-A expression in human lymphomas and its relation to tumor aggressiveness.","volume":"74","author":"Aryee","year":"1996","journal-title":"Br J Cancer."},{"key":"2020021220265330000_B19","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood.V94.10.3541.422k15_3541_3550","article-title":"Prognostic implications of the differentiation inhibitory factor nm23\u2013H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.","volume":"94","author":"Niitsu","year":"1999","journal-title":"Blood."},{"key":"2020021220265330000_B20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"2020021220265330000_B21","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification.","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"2020021220265330000_B22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1600-0609.1996.tb01336.x","article-title":"Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.","volume":"56","author":"Niitsu","year":"1996","journal-title":"Eur J Haematol."},{"key":"2020021220265330000_B23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/1097-0142(19920201)69:3<772::AID-CNCR2820690326>3.0.CO;2-Z","article-title":"Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.","volume":"69","author":"Hirano","year":"1992","journal-title":"Cancer."},{"key":"2020021220265330000_B24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-5793(95)00338-A","article-title":"A new function of Nm23\/NDP kinase as a differentiation inhibitory factor, which does not require its kinase activity.","volume":"363","author":"Okabe-Kado","year":"1995","journal-title":"FEBS Lett."},{"key":"2020021220265330000_B25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021220265330000_B26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2307\/3001968","article-title":"Individual comparisons by ranking methods.","volume":"1","author":"Wilcoxon","year":"1945","journal-title":"Biometrics Bull."},{"key":"2020021220265330000_B27","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"2020021220265330000_B28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J Stat Soc Br."},{"key":"2020021220265330000_B29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0006-291X(92)91829-F","article-title":"Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23\/nucleoside diphosphate kinase.","volume":"182","author":"Okabe-Kado","year":"1992","journal-title":"Biochem Biophys Res Commun."},{"key":"2020021220265330000_B30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0167-4889(95)00037-S","article-title":"Inhibitory action of nm23 proteins on induction of erythroid differentiation of human leukemia cells.","volume":"1267","author":"Okabe-Kado","year":"1995","journal-title":"Biochim Biophys Acta."},{"key":"2020021220265330000_B31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/0959-8049(95)00152-9","article-title":"The potential roles of nm23 in cancer metastasis and cellular differentiation.","volume":"31A","author":"MacDonald","year":"1995","journal-title":"Eur J Cancer."},{"key":"2020021220265330000_B32","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood.V88.9.3555.bloodjournal8893555","article-title":"Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia.","volume":"88","author":"Yokoyama","year":"1996","journal-title":"Blood."},{"key":"2020021220265330000_B33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10428199809059243","article-title":"Differentiation inhibitory factor Nm23 as a prognostic factor for acute myeloid leukemia.","volume":"32","author":"Okabe-Kado","year":"1998","journal-title":"Leuk Lymphoma."},{"key":"2020021220265330000_B34","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.V96.3.1080","article-title":"Plasma levels of the differentiation inhibitory factor nm23\u2013H1 protein and their clinical implication in acute myelogenous leukemia.","volume":"96","author":"Niitsu","year":"2000","journal-title":"Blood."},{"key":"2020021220265330000_B35","first-page":"483","article-title":"Current approaches to the management of non-Hodgkin's lymphoma.","volume":"25","author":"Vose","year":"1998","journal-title":"Semin Oncol."},{"key":"2020021220265330000_B36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/5\/1202\/1671769\/1202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/5\/1202\/1671769\/1202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:11:12Z","timestamp":1733703072000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/5\/1202\/107366\/Serum-nm23H1-protein-as-a-prognostic-factor-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.5.1202","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,3,1]]}}}